Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Business Wire10/15/2026Neutral
MIRM
Mirum Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$5.20B
P/E Ratio
—
EPS
$-14.10
Beta
0.61
52W High
$130.00
52W Low
$63.23
50-Day MA
$93.05
200-Day MA
$98.52
Dividend Yield
—
Profit Margin
-139.20%
Forward P/E
166.67
PEG Ratio
—
About Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of an advanced line of novel therapies for debilitating liver diseases. The company is headquartered in Foster City, California.
Fundamentals
| Revenue (TTM) | $618.07M |
| Gross Profit (TTM) | $505.11M |
| EBITDA | $-70.28M |
| Operating Margin | -14.80% |
| Return on Equity | -703.00% |
| Return on Assets | -6.79% |
| Revenue/Share (TTM) | $11.02 |
| Book Value | $-0.16 |
| Price-to-Book | 26.59 |
| Price-to-Sales (TTM) | 8.42 |
| EV/Revenue | 9.91 |
| EV/EBITDA | 341.15 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 37.90% |
| Shares Outstanding | $64.93M |
| Float | $56.40M |
| % Insiders | 1.31% |
| % Institutions | 111.81% |
Historical Volatility
HV 10-Day
58.36%
HV 20-Day
42.15%
HV 30-Day
43.82%
HV 60-Day
47.84%
HV Rank
39.7%
Volatility is currently expanding
Analyst Ratings
Consensus ($153.07 target)
4
Strong Buy10
BuyLatest News
Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases
MIRM's Livmarli meets the phase III EXPAND study goal, improving cholestatic pruritus and reducing serum bile acids, with an FDA filing planned for 2027.
Zacks Investment Research10/13/2026Positive
Mirum Pharmaceuticals' LIVMARLI Study Hits Key Endpoints in Rare Liver Diseases
Mirum Pharmaceuticals NASDAQ: MIRM said its Phase III EXPAND study of LIVMARLI, or maralixibat, met its primary endpoint and all prespecified secondary endpoints in pediatric patients with cholestatic pruritus associated with ultra-rare cholestatic liver diseases.
MarketBeat10/12/2026Positive
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum to Host Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases.
Business Wire10/11/2026Neutral
Mirum Pharmaceuticals' Brevlovitug Hits Phase III Endpoint in Hepatitis Delta Study
Mirum Pharmaceuticals NASDAQ: MIRM reported positive top-line results from the Phase III portion of its AZURE-1 study evaluating brelovitug for chronic hepatitis delta, saying the investigational antibody met its primary endpoint at 24 weeks and showed a favorable tolerability profile.
MarketBeat10/2/2026Positive
Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV
MIRM's brelovitug meets the phase III AZURE-1 goal in chronic hepatitis delta virus, with strong virologic response and ALT normalization rates.
Zacks Investment Research9/29/2026Positive
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Transcript
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Transcript
Seeking Alpha9/28/2026Neutral
MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy
Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP, backed by PROGRESS data showing a reduction in new HO lesion volume.
Zacks Investment Research9/28/2026Positive
Mirum's liver infection drug lowers virus levels in late-stage study
Mirum Pharmaceuticals on Monday said its experimental hepatitis drug reduced levels of the virus in patients, meeting the main goal of a late-stage study.
Reuters9/28/2026Positive
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus.
Business Wire9/28/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MIRM and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 10/17/2026